Development
Sarepta Therapeutics, Inc.
SRPT
$16.26
-$0.49-2.93%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 141.79% | 84.12% | 89.66% | -392.03% | 10.44% |
| Total Depreciation and Amortization | 7.76% | 2.10% | 9.13% | 5.47% | 5.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.08% | -59.31% | -156.76% | 1,059.98% | 57.56% |
| Change in Net Operating Assets | -192.43% | -1,649.29% | -203.47% | -196.56% | -211.98% |
| Cash from Operations | 40.84% | -76.57% | -82.94% | -106.96% | -215.05% |
| Capital Expenditure | -139.06% | -260.50% | -97.28% | -70.87% | -261.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -355.17% | -761.42% | 140.78% | 102.82% | 4,887.06% |
| Cash from Investing | -756.98% | -1,201.37% | 133.32% | 101.59% | 480.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -82.81% | 14.87% | 1,628.91% | 461.86% | -97.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -- |
| Cash from Financing | -81.92% | -92.88% | 1,628.91% | 1,939.98% | -98.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.95% | -281.65% | 94.46% | 89.22% | -113.89% |